Merck Highlights Cutting-Edge Advances in Treating Advanced Cancers and Rare Tumors at ASCO 2025
Merck Highlights Breakthrough Innovations in Advanced Cancers and Rare Tumors at ASCO 2025 Merck, a global leader in science and technology, has once again showcased its commitment to transforming cancer…
US FDA Grants Approval for Nucala (Mepolizumab) to Treat Adults with Chronic Obstructive Pulmonary Disease (COPD)
GSK’s Nucala (Mepolizumab) Receives US FDA Approval as Add-On Maintenance Treatment for Adults with Eosinophilic Phenotype COPD GSK has officially announced a significant milestone in the treatment of chronic obstructive…
Dr. Mark Stetter Joins Zoetis Board of Directors Following Election
Dr. Mark Stetter Elected to Zoetis Board of Directors, Bringing Decades of Veterinary Leadership and Animal Health Expertise Zoetis,a global leader in animal health, announced a significant addition to its…
Linvoseltamab Combos Show Early Promise in Relapsed/Refractory Multiple Myeloma
Regeneron’s Linvoseltamab Combinations Show Strong Early Signals in Relapsed/Refractory Multiple Myeloma in Phase 1b Trial Regeneron Pharmaceuticals,has reported encouraging early findings from the ongoing Phase 1b LINKER-MM2 study, evaluating linvoseltamab…
Bristol Myers Squibb to Showcase Oncology Pipeline and Research at ASCO 2025
Bristol Myers Squibb Showcases Expansive Oncology Portfolio and Groundbreaking Clinical Research at ASCO 2025 Annual Meeting Bristol Myers Squibb is set to make a significant impact at the 2025 American…
XTANDI Demonstrates Long-Term Survival in Metastatic Prostate Cancer
XTANDI Delivers Sustained Five-Year Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer: Landmark Findings from ARCHES and ENZAMET Trials Presented at ASCO 2025 Astellas Pharma Inc. and Pfizer Inc. have announced…
FDA Grants Approval to Roche’s Susvimo for Treatment of Diabetic Retinopathy
FDA Approves Roche’s Susvimo as the First and Only Continuous-Delivery Treatment for Diabetic Retinopathy, Offering Nine-Month Dosing Durability In a significant advancement for patients suffering from diabetic retinopathy (DR), the…
Lilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment
Lilly’s Kisunla (Donanemab) Gains Marketing Authorization in Australia for Early Alzheimer’s Treatment Eli Lilly and Company has announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for…
Addressing Barriers: An Open Letter on Obesity Care and Insurance Access
A Call for Change: Ensuring Access and Insurance Coverage for People Living with Obesity In recent months, abrupt changes to insurance coverage for obesity management medications have placed thousands of…
AstraZeneca Marks 7th Year of ASCO Plenary Data, Advancing Breast and Gastric Cancer Care
AstraZeneca Showcases Broad Oncology Leadership with More Than 80 Abstracts and Two Plenary Presentations at ASCO 2025, Reinforcing Ambition to Eliminate Cancer as a Cause of Death AstraZeneca is poised…
Sanofi to Acquire Vigil Neuroscience, Boosting Alzheimer’s Drug Pipeline
Sanofi to Acquire Vigil Neuroscience in $470 Million Deal, Bolstering Neurology Pipeline with Promising Alzheimer’s Drug Candidate In a strategic move that further solidifies its commitment to neurological disorders, Sanofi…
Merck Reports Positive Phase 2 Results for Enpatoran in Lupus Patients
Merck Unveils Positive Phase 2 Results for Enpatoran, Showing Significant Reduction in Disease Activity in Patients with Cutaneous and Systemic Lupus with Active Rash Merck, a global leader in science…